Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment. Head Neck 2014 Mar;36(3):E25-7
Date
07/16/2013Pubmed ID
23852769Pubmed Central ID
PMC3893310DOI
10.1002/hed.23429Scopus ID
2-s2.0-84894228106 (requires institutional sign-in at Scopus site) 44 CitationsAbstract
BACKGROUND: Salivary ductal carcinoma is a rare cancer with poor prognosis and limited treatment options. Human epidermal receptor 2 (HER2)-directed treatment has been attempted in HER2-amplified or overexpressed salivary gland malignancies with limited success.
METHODS: We report resolution of measurable disease and minimal residual disease in a patient with salivary duct cancer treated with trastuzumab, lapatinib, and bevacizumab, with treatment ongoing for more than 2 years.
RESULTS: This treatment has been tolerated well except for grade 2 diarrhea and mucositis, which required a dose reduction of lapatinib to 1000 mg daily. The response observed was achieved in spite of receiving extensive prior therapy, including trastuzumab and/or chemotherapy for 20 months on which his tumors progressed.
CONCLUSION: The combination of trastuzumab, lapatinib, and bevacizumab may warrant investigation as a non-cytotoxic alternative for treatment of HER2-amplified or overexpressed salivary duct carcinoma and other HER2-amplified or overexpressed salivary gland tumors, particularly those not responsive to trastuzumab monotherapy.
Author List
Falchook GS, Lippman SM, Bastida CC, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
Aged, 80 and overAngiogenesis Inhibitors
Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Bevacizumab
Drug Therapy, Combination
Gene Expression Regulation, Neoplastic
Humans
Immunohistochemistry
Male
Middle Aged
Neoplasm, Residual
Quinazolines
Receptor, ErbB-2
Salivary Ducts
Salivary Gland Neoplasms
Trastuzumab
Vascular Endothelial Growth Factor A
